Tyrphostin AG 1296
(Synonyms: AG1296) 目录号 : GC13045
An inhibitor of PDGF receptor kinase
Cas No.:146535-11-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Swiss 3T3 cells, porcine aortic endothelial cells, sis-transformed cells |
|
Preparation method |
The solubility of this compound in DMSO is > 6.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
6-8 h |
|
Applications |
AG1296 (0.1-5 μM) dose-dependently inhibited the activity of PDGF receptor kinase in Swiss 3T3 cell membranes. AG1296 inhibited PDGF receptor autophosphorylation with an IC50 of 0.3-0.5 μM. AG1296 was also highly inhibitory towards PDGF-induced mitogenesis. AG1296 inhibited the mitogenic effect of basic FGF on Swiss 3D cells, albeit with an IC50 of 12.3 ± 3.1 μM. AG1296 potently inhibited PDGF-induced cell growth (IC50: 3.2 μM). In porcine aortic endothelial cells, AG1296 inhibited autophosphorylation of both human PDGFα- and PDGFβ-receptor and inhibited equipotently PDGFα- and PDGFβ-receptor -dependent DNA synthesis in cells transfected with either receptor. AG1296 (5-50 μM) potently inhibited the growth of the sis-transformed NIH 3T3 cells. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Kovalenko M, Gazit A, Bhmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation[J]. Cancer Research, 1994, 54(23): 6106-6114. | |
Tyrphostin AG 1296 is a selective inhibitor of platelet-derived growth factor receptor (PDGFR) with IC50 value of 0.3μM-0.5μM [1].
Tyrphostin AG 1296 is an ATP-competitive inhibitor of PDGFR. It binds to PDGFR, causing a conformational change at the ATP-binding site. In the in vitro assay, it potently inhibits the ligand-induced autophosphorylation of PDGF receptor in Swiss 3T3 cell membranes. Tyrphostin AG 1296 does not affect the EGF receptor when the concentration is up to 100μM. Tyrphostin AG 1296 also inhibits the mitogenesis induced by PDGF but not EGF or insulin. It reversibly inhibits PDGF-induced DNA synthesis with a mean IC50 value of 1.5μM. Besides that, tyrphostin AG 1296 inhibits PDGF-induced cell growth with IC50 value of 3.2μM in Swiss 3T3 cells [1, 2].
References:
[1] Kovalenko M, Gazit A, Böhmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Research, 1994, 54(23): 6106-6114.
[2] Kovalenko M, Rönnstrand L, Heldin C H, et al. Phosphorylation site-specific inhibition of platelet-derived growth factor β-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry, 1997, 36(21): 6260-6269.
| Cas No. | 146535-11-7 | SDF | |
| 别名 | AG1296 | ||
| 化学名 | 6,7-dimethoxy-2-phenylquinoxaline | ||
| Canonical SMILES | COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC | ||
| 分子式 | C16H14N2O2 | 分子量 | 266.29 |
| 溶解度 | ≥ 6.65mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7553 mL | 18.7765 mL | 37.553 mL |
| 5 mM | 0.7511 mL | 3.7553 mL | 7.5106 mL |
| 10 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。